UBT251 vs BI 456906
Head-to-head comparison of UBT251 (UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist) and BI 456906 (BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
| Property | UBT251 | BI 456906 |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | UBT251, glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide/glucagon receptor triagonist | BI 456906, glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | N/A | N/A |
| Half-Life | Approximately 1 week | Approximately 1 week |
| Amino Acids | N/A | N/A |
| Typical Dose | Investigational; no established human dose | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 8 | 10 |
| Research Status | Pre-clinical | Clinical |
UBT251 Benefits
- ✓weight reduction
- ✓improved satiety
- ✓enhanced energy expenditure
- ✓better insulin sensitivity
BI 456906 Benefits
- ✓weight reduction
- ✓improved glucose control
- ✓lower liver-fat burden
- ✓enhanced satiety
UBT251 Dosing
once-weekly subcutaneous injection|dose escalation in studies|maintenance after tolerability assessment
BI 456906 Dosing
once-weekly subcutaneous injection|stepwise titration|ongoing maintenance phase
UBT251 Side Effects
- ⚠nausea
- ⚠diarrhea
- ⚠fatigue
BI 456906 Side Effects
- ⚠nausea
- ⚠abdominal discomfort
- ⚠diarrhea
Research Overview
UBT251
Published work supports strong anti-obesity activity in preclinical models, with translation into human studies still emerging. The compound remains investigational and is best characterized as an early multi-agonist program.
BI 456906
Preclinical and early clinical research support meaningful metabolic effects with a tolerable safety profile. It remains investigational and is not commercially available.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.